Gilead Sciences Inc. (GILD)
NASDAQ: GILD
· Real-Time Price · USD
118.49
-0.53 (-0.45%)
At close: Aug 15, 2025, 3:10 PM
Gilead Sciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 7.08B | 6.67B | 7.57B | 7.54B | 6.95B | 6.69B | 7.11B | 7.05B | 6.6B | 6.35B | 7.39B | 7.04B | 6.26B | 6.59B | 7.24B | 7.42B | 6.22B | 6.42B |
Cost of Revenue | 1.5B | 1.54B | 1.58B | 1.57B | 1.54B | 1.55B | 2.09B | 1.56B | 1.44B | 1.4B | 1.4B | 1.4B | 1.44B | 1.42B | 2.63B | 1.22B | 1.39B | 1.36B |
Gross Profit | 5.58B | 5.13B | 5.99B | 5.97B | 5.41B | 5.13B | 5.02B | 5.49B | 5.16B | 4.95B | 5.99B | 5.65B | 4.82B | 5.17B | 4.62B | 6.2B | 4.83B | 5.06B |
Operating Income | 2.47B | 2.24B | 2.45B | 888M | 2.64B | -4.32B | 1.61B | 2.62B | 1.67B | 1.71B | 2.27B | 2.84B | 2.03B | 197M | 940M | 3.84B | 2.25B | 2.89B |
Interest Income | 73M | 94M | 85M | 52M | 35M | 108M | n/a | 106M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 2.43B | 1.65B | 2.17B | 956M | 2.05B | -4.49B | 1.65B | 2.32B | 1.59B | 1.3B | 2.03B | 2.43B | 1.5B | -152M | 759M | 3.44B | 1.82B | 2.26B |
Net Income | 1.96B | 1.31B | 1.78B | 1.25B | 1.61B | -4.17B | 1.43B | 2.18B | 1.04B | 1.01B | 1.64B | 1.79B | 1.14B | 19M | 382M | 2.59B | 1.52B | 1.73B |
Selling & General & Admin | 1.36B | 1.26B | 1.86B | 1.43B | 1.38B | 1.38B | 1.58B | 1.31B | 1.85B | 1.32B | 2.02B | 1.21B | 1.36B | 1.08B | 1.65B | 1.19B | 1.35B | 1.05B |
Research & Development | 1.49B | 1.38B | 1.64B | 1.4B | 1.35B | 1.52B | 1.41B | 1.46B | 1.41B | 1.45B | -1.15B | 1.15B | 1.1B | 3.88B | 2.03B | 1.1B | 1.09B | 1.05B |
Other Expenses | 250M | 253M | 34M | 2.25B | 37M | 6.56B | 424M | 90M | 236M | 480M | 2.86B | 448M | 330M | 8M | n/a | 65M | 138M | 62M |
Operating Expenses | 3.11B | 2.89B | 3.54B | 5.08B | 2.77B | 9.46B | 3.41B | 2.86B | 3.49B | 3.25B | 3.73B | 2.81B | 2.79B | 4.97B | 3.68B | 2.36B | 2.58B | 2.17B |
Interest Expense | 254M | 260M | 249M | 238M | 237M | 254M | 252M | 232M | 230M | 230M | 226M | 229M | 242M | 238M | 238M | 250M | 256M | 257M |
Selling & Marketing Expenses | 864M | 753M | 869M | n/a | 805M | 743M | 826M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.61B | 4.43B | 5.12B | 6.66B | 4.31B | 11.01B | 5.5B | 4.43B | 4.93B | 4.65B | 5.12B | 4.21B | 4.23B | 6.39B | 6.3B | 3.58B | 3.97B | 3.53B |
Income Tax Expense | 468M | 334M | 385M | -297M | 438M | -315M | 237M | 146M | 549M | 316M | 398M | 646M | 368M | -164M | 383M | 852M | 300M | 542M |
Shares Outstanding (Basic) | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.26B | 1.25B | 1.26B | 1.26B | 1.25B | 1.26B |
Shares Outstanding (Diluted) | 1.25B | 1.26B | 1.26B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B |
EPS (Basic) | 1.57 | 1.06 | 1.43 | 1.00 | 1.29 | -3.34 | 1.15 | 1.75 | 0.84 | 0.81 | 1.31 | 1.43 | 0.91 | 0.01 | 0.30 | 2.06 | 1.21 | 1.38 |
EPS (Diluted) | 1.56 | 1.04 | 1.42 | 1.00 | 1.29 | -3.34 | 1.14 | 1.73 | 0.83 | 0.80 | 1.30 | 1.42 | 0.91 | 0.01 | 0.30 | 2.05 | 1.21 | 1.37 |
EBITDA | 3.37B | 2.6B | 3.11B | 1.88B | 2.98B | -3.54B | 2.59B | 3.23B | 2.5B | 2.17B | 2.79B | 3.19B | 2.27B | 611M | 1.53B | 4.21B | 2.59B | 2.99B |
EBIT | 2.68B | 1.91B | 2.42B | 1.19B | 2.29B | -4.23B | 1.91B | 2.55B | 1.82B | 1.53B | 2.26B | 2.66B | 1.75B | 86M | 997M | 3.69B | 2.07B | 2.52B |
Depreciation & Amortization | 691M | 696M | 693M | 690M | 694M | 690M | 688M | 684M | 681M | 640M | 528M | 525M | 525M | 525M | 535M | 523M | 519M | 473M |